DOYLESTOWN, Pa.--(BUSINESS WIRE)--QuantRx® Biomedical Corporation (OTCBB:QTXB), a broad-based diagnostics company focused on the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide healthcare industry, is pleased to announce that QuantRx’s FluoroPharma, Inc. has been issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG), by the United States Patent and Trademark Office. This patent, exclusively licensed from the Massachusetts General Hospital (MGH), provides FluoroPharma with additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.
